Heron Therapeutics Inc - Rasio nilai perusahaan marang dodolan HRTX

Simbol resmi perusahaan Heron (HRTX)

Stable demand for hospital drugs ensures high macro-resilience for Heron Therapeutics (HRTX). The current EV/Sales ratio reflects the company's enterprise value relative to revenue excluding debt, fixing the metric at 1076.64. Growth is driven by the integration of analgesics into medical protocols. Heron Therapeutics is pursuing its path to profitability independently by expanding distribution through partnerships with logistics operators.

Heron Therapeutics, Inc. (HRTX): Nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

Heron Therapeutics, Inc. - rincian analitis lan metrik utama (HRTX)

- rega lan prakiraan konsensus rega:
- data saldo dhuwit lan arus kas:
Pambiji fundamental perusahaan:HRTX, Heron Therapeutics Inc
Produk sing diprodhuksi herontx.com

This indicator determines the market value of the business, accounting for net debt per unit of generated revenue. The EV/Sales ratio trend allows analysts to filter out price volatility and identify real trends in asset revaluation by institutional capital. This metric shows how much an investor pays for current turnover, excluding the impact of the debt load. For Heron Therapeutics (HRTX), an increase in this ratio may reflect market expectations regarding the implementation of robotic packaging and the digitalization of logistics. Warehouse automation reduces costs, potentially increasing the efficiency of every unit of revenue.

Analisis pesaing

Multiplikator nilai perusahaan marang pendapatan Incyte Corporation|HCM (HUTCHMED Corp) - Nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang dodolan Nuvation Pharma NUVB|Nilai perusahaan marang pendapatan DAWN|Multiplikator nilai perusahaan marang pendapatan Monopar Therapeutics MNPR|Nilai perusahaan marang pendapatan INBX (Inhibrx Biosciences)|IMAB (I-Mab Inc.) - Nilai bisnis marang pendapatan|Fennec Pharmaceuticals - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan NVCT (Nuvectis Pharma)|Coherus BioSciences, Inc. - Multiplikator EV/Sales|Nilai bisnis marang pendapatan CRBP (Corbus Pharma)|CRDF: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan beyondspringpharma.com (BYSI)|Rasio nilai perusahaan marang pendapatan bioatla.com|LIXT: Nilai bisnis marang pendapatan|Multiplikator EV/Sales CTXR|Multiplikator EV/Sales Cellectar Corp (CLRB)|Rasio nilai perusahaan marang pendapatan BioLineRx Corp BLRX|CANF (Can-Fite BioPharma Ltd.) - Nilai perusahaan marang volume dodolan|APRE: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Kazia Therapeutics Limited|Silexion Therapeutics Corp (SLXN) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan NCNA|CMRX (Chimerix, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Nilai bisnis marang pendapatan|KRON - Multiplikator nilai perusahaan marang pendapatan|Kintara Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan ONCT (Oncternal)|Portage Biotech Corp - Multiplikator EV/Sales